Trevi Therapeutics(TRVI)
$13.510.00 (0.00%)
TRVI
Trevi Therapeutics financials statements
$13.51
At close:0.00 (0.00%)
Want to see TRVI full AI Analyst Report?
Trevi Therapeutics (TRVI) Ratios
611 Followers
Trevi Therapeutics Ratios
TRVI's free cash flow for Q3 2026 was $-19.71M. For the 2026 fiscal year, TRVI's free cash flow was decreased by $-25.00K and operating cash flow was $-19.69M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 19.66 | 10.41 | 15.03 | 9.15 | 2.98 |
| Quick Ratio | 19.66 | 10.41 | 15.03 | 9.15 | 2.98 |
| Cash Ratio | 1.94 | 3.24 | 5.56 | 0.94 | 2.89 |
| Solvency Ratio | -4.18 | -4.24 | -4.22 | -1.87 | -1.58 |
| Operating Cash Flow Ratio | -4.32 | -3.64 | -5.44 | -2.10 | -2.27 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -4.03 | -4.96 |
| Net Current Asset Value | $ 181.46M | $ 98.17M | $ 80.69M | $ 107.06M | $ 16.56M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.01 | 0.07 | 0.38 |
| Debt-to-Equity Ratio | 0.00 | 0.01 | 0.02 | 0.09 | 0.86 |
| Debt-to-Capital Ratio | 0.00 | 0.01 | 0.02 | 0.08 | 0.46 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.34 |
| Financial Leverage Ratio | 1.06 | 1.11 | 1.08 | 1.14 | 2.25 |
| Debt Service Coverage Ratio | 0.00 | -11940.00 | -73.02 | -3.59 | -4.65 |
| Interest Coverage Ratio | 0.00 | -12881.00 | -86.76 | -38.34 | -27.02 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.07 | 0.81 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.02 | 0.15 | 0.69 |
| Net Debt to EBITDA | 0.43 | 0.69 | 1.09 | 0.12 | 0.68 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 99.85% | 99.94% | 99.89% | 99.88% | 99.94% |
| EBT Per EBIT | 86.81% | 93.05% | 85.77% | 97.60% | 104.57% |
| Return on Assets (ROA) | -22.10% | -43.20% | -32.51% | -23.70% | -88.21% |
| Return on Equity (ROE) | -23.33% | -48.08% | -35.21% | -27.13% | -198.77% |
| Return on Capital Employed (ROCE) | -26.85% | -51.32% | -40.59% | -27.28% | -126.12% |
| Return on Invested Capital (ROIC) | -26.77% | -51.15% | -40.40% | -25.61% | -102.37% |
| Return on Tangible Assets | -22.10% | -43.20% | -32.51% | -23.70% | -88.21% |
| Earnings Yield | -2.35% | -11.51% | -21.90% | -23.40% | -189.96% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.29 | -0.38 | -0.32 | -0.44 | -1.27 |
| Free Cash Flow Per Share | -0.29 | -0.38 | -0.32 | -0.44 | -1.27 |
| Dividend Paid and CapEx Coverage Ratio | -3507.42 | -1093.03 | -231.46 | -177.20 | 0.00 |
| Capital Expenditure Coverage Ratio | -3507.42 | -1093.03 | -231.46 | -177.20 | 0.00 |
| Operating Cash Flow Coverage Ratio | -55.90 | -37.07 | -23.70 | -3.07 | -1.98 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -2.32% | -9.20% | -24.00% | -22.75% | -162.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -43.17 | -8.77 | -4.57 | -4.27 | -0.53 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 9.91 | 4.18 | 1.61 | 1.16 | 1.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -43.15 | -10.87 | -4.17 | -4.40 | -0.62 |
| Price-to-Operating Cash Flow Ratio | -43.16 | -10.88 | -4.18 | -4.42 | -0.62 |
| Price-to-Earnings Growth (PEG) Ratio | 1.13 | -0.14 | 0.13 | 0.06 | 0.03 |
| Enterprise Value Multiple | -42.14 | -8.02 | -3.56 | -4.33 | 0.13 |
| Enterprise Value | 1.80B | 383.23M | 101.65M | 121.15M | -4.33M |
| EV to EBITDA | -42.14 | -8.02 | -3.56 | -4.33 | 0.13 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -42.72 | -10.01 | -3.19 | -4.28 | 0.15 |
| EV to Operating Cash Flow | -42.73 | -10.02 | -3.21 | -4.30 | 0.15 |
| Tangible Book Value Per Share | 1.26 | 0.99 | 0.83 | 1.66 | 0.75 |
| Shareholders’ Equity Per Share | 1.26 | 0.99 | 0.83 | 1.66 | 0.75 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.29 | -0.47 | -0.29 | -0.45 | -1.49 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.01 | 1.04 | 1.04 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.98 | 0.80 | 1.09 | 0.97 | 0.85 |
Currency in USD

